A 14-year study tracking NfL levels in people with the HD gene shows this tiny protein can signal disease progression many ...

Celltrion Inc., a major South Korean biopharmaceutical firm, said Thursday it has launched its biosimilar product for Stelara ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

According to the University of California San Francisco, Huntington’s disease affects one in every 10,000 to 20,000 people in ...

SAN DIEGO, CA, USA I March 5, 2025 I Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the ...

The therapy joins another VMAT2 inhibitor, NBI-1065890, which is undergoing assessment by the company in Phase I trials.

Multiple system atrophy (MSA) is not exactly a household word – a situation that Alterity Therapeutics is seeking to change.

Huntington’s disease was long thought to be caused by the slow buildup of a toxic protein, but new research has revealed that it’s actually driven by the expansion of a gene that, at a certain ...

ClearPoint's Q4 updates: neurosurgery growth, expanding services, controlled cash burn and high-potential partner programs driving future prospects. See more here.

Treating these conditions is particularly challenging because of the small patient population, making it hard to conduct trials and properly understand the disease. Medicines that are used to treat ...